
Pre-made Amatuximab benchmark antibody ( Whole mAb, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-020
Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-020-1mg | 1mg | 3090 | ||
GMP-Bios-ab-020-10mg | 10mg | 21890 | ||
GMP-Bios-ab-020-100mg | 100mg | 148000 | ||
GMP-Bios-ab-020-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody |
INN Name | Amatuximab |
Target | MSLN |
Format | Whole mAb |
Derivation | Chimeric (Mouse/Human) |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | 4f33:BA:DC:FE:HG/4f3f:BA |
95-98% SI Structure | None |
Year Proposed | 2010 |
Year Recommended | 2011 |
Companies | Eisai Co Ltd;Morphotek;National Cancer Institute (USA) |
Conditions Approved | na |
Conditions Active | Mesothelioma |
Conditions Discontinued | Pancreatic cancer;Solid tumours |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
